Article
Lamivudine as initial treatment for chronic hepatitis B in the United States.
The New England journal of medicine - 21 Oct 1999
Dienstag J L, Schiff E R, Wright T L, Perrillo R P, Hann H W, Goodman Z, Crowther L, Condreay L D, Woessner M, Rubin M, Brown N A
Abstract excerpt
BACKGROUND AND METHODS: Although the nucleoside analogue lamivudine has shown promise in patients with chronic hepatitis B, long-term data on patients from the United States are lacking. We randomly assigned previously untreated patients with chronic hepatitis B to receive either 100 mg of oral lamivudine or placebo daily for 52 weeks. We then followed them for an additional 16 weeks to evaluate post-treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.